The U.S. Court of Appeals for the Federal Circuit recently dismissed an appeal by Teva Pharmaceuticals USA Inc., affirming the validity of a Johnson & Johnson subsidiary’s patent for a profitable schizophrenia medication. The court refuted Teva’s argument that the patent’s claims should be considered obvious. This decision represents a victory for Johnson & Johnson in safeguarding its intellectual property rights against generic pharmaceutical competitors.
This case highlights the ongoing challenges faced by generic drug manufacturers in contesting the patents of brand-name pharmaceuticals. For further details, the original article can be accessed through Law360.